bioRxiv Science⌕ Search

Biology subjects

Soe, K.

Publications and source records attributed to Soe, K..

3 recordsLinked to original sources

Stage-Specific Modulation of Multinucleation, Fusion and Resorption by the Long Non-coding RNA DLEU1 and miR-16 in Human Primary Osteoclasts

Osteoclasts are multinucleated cells formed through fusion of mononucleated precursors of the myeloid lineage and are the only cells that can resorb all the constituents of the bone matrix. Our goal was to investigate the role of long non-coding RNA DLEU1 and miR-16-5p in the fusion of human primary osteoclasts and their resorptive capacity. We found DLEU1 to be markedly upregulated, whereas miR-16 was significantly suppressed, during osteoclast differentiation, suggesting a potential involvement in the multinucleation process. The knockdown of DLEU1 or the overexpression of miR-16 in human primary pre-osteoclasts from male human donors (50 years or older) impaired fusion at both early and late time-points, each in distinct ways, without affecting cell viability. Time-lapse recordings confirmed the impairment of the fusion process and showed an abrogation of the phagocytic cup fusion modality, as well as a reduction of the fusion between mononucleated precursors and multinucleated osteoclasts during DLEU1 silencing. Furthermore, mass spectrometry-based quantitative proteomics revealed that the effects of DLEU1 and miR-16 on osteoclast fusion were mediated by distinct proteins and processes. Thus, both DLEU1 inhibition and/or miR-16 overexpression hinder osteoclast fusion through modulation of different mechanisms. Moreover, decreased levels of DLEU1 specifically affected the resorption speed of pit-making osteoclasts, while increased levels of miR-16 promoted bone resorption mainly through pit-formation, impairing the resorption speed of the osteoclasts making trenches and affecting their resorbed area. Taken together, these findings identify DLEU1 and miR-16 as mediators of osteoclast fusion and activity, offering potential new therapeutic targets to ameliorate bone destruction in skeletal diseases with accentuated bone deterioration.

molecular biology↗

GIP receptor reduces osteoclast activity and improves osteoblast survival by activating multiple signaling pathways

Bone is a dynamic tissue that is remodeled throughout life by bone resorbing osteoclasts and bone forming osteoblasts, to adapt to physiological or mechanical demands. These processes are impaired in osteoporosis, and understanding how bone remodeling is regulated could improve anti-osteoporotic treatments. Clinical investigations show that short-term treatment with glucose-dependent insulinotropic polypeptide (GIP) acutely decreases serum markers of bone resorption and may increase bone formation. However, evidence for direct effects of GIP intracellular signaling and functions in mature human osteoclasts and osteoblasts have not been investigated. We report that the GIP receptor (GIPR) is robustly expressed in mature human osteoclasts. Exposure of osteoclasts to GIP inhibits osteoclastogenesis, delays bone resorption, and increases osteoclast apoptosis by acting upon multiple signaling pathways (cAMP, Src, Akt, calcium, p38) to impair nuclear translocation of nuclear factor of activated T cells 1 (NFATc1) and nuclear factor-{kappa}B (NF{kappa}B). Human osteoblasts also express GIPR, and GIP improves osteoblast survival via cAMP and Akt-mediated pathways. GIP treatment of co-cultures of osteoclasts and osteoblasts also decreased bone resorption. Antagonizing GIPR with GIP(3-30)NH2 abolished the effects of GIP on osteoclasts and osteoblasts. This study demonstrates that GIP inhibits bone resorption and improves survival of human osteoblasts, which could increase bone mass and strength, supporting clinical investigations of the effect of GIP on bone. Moreover, this study demonstrates that GIPR agonism could be beneficial in the treatment of disorders of bone remodeling, such as osteoporosis. One-sentence SummaryGIP acts directly on bone cells to regulate bone remodeling

cell biology↗

Sugar transporter Slc37a2 regulates bone metabolism via a dynamic tubular lysosomal network in osteoclasts

Osteoclasts are giant bone-digesting cells that harbour specialized lysosome-related organelles termed secretory lysosomes (SLs). SLs store cathepsin K and serve as a membrane precursor to the ruffled border, the osteoclasts resorptive apparatus. Yet, the molecular composition and spatiotemporal organization of SLs remains incompletely understood. Here, using organelle-resolution proteomics, we identify member a2 of the solute carrier 37 family (Slc37a2) as a SL sugar transporter. We demonstrate that Slc37a2 localizes to the SL limiting membrane and that these organelles adopt a hitherto unnoticed but dynamic tubular network in living osteoclasts that is required for bone digestion. Accordingly, mice lacking Slc37a2 accrue high bone mass owing to uncoupled bone metabolism and disturbances in SL export of monosaccharide sugars, a prerequisite for SL delivery to the ruffled border. Thus, Slc37a2 is a physiological component of the osteoclasts unique secretory organelle and a potential therapeutic target for metabolic bone diseases.

cell biology↗